Are you Dr. Costello?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 93 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Brian Costello, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Connecticut, and Tennessee. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2009
- University of New Mexico School of MedicineResidency, Internal Medicine, 1995 - 1998
- Medical College of WisconsinClass of 1995
Certifications & Licensure
- AZ State Medical License 2013 - 2026
- ND State Medical License 2014 - 2026
- MT State Medical License 2014 - 2026
- MI State Medical License 2013 - 2026
- WI State Medical License 2013 - 2025
- MN State Medical License 1998 - 2025
- IA State Medical License 2013 - 2024
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Start of enrollment: 2009 Sep 01
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsDevelopment and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal Metastases.Roman O Kowalchuk, Benjamin A Johnson-Tesch, Joseph T Marion, Trey C Mullikin, William S Harmsen
JAMA Oncology. 2022-03-01 - 11 citationsEvaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.Ahmed M Mahmoud, Igor Frank, Jacob J Orme, Roxane R Lavoie, Prabin Thapa
BMC Urology. 2022-06-24 - 426 citationsKidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam B. Bhayani, William P Bro
Journal of the National Comprehensive Cancer Network. 2017-06-01
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020